211 related articles for article (PubMed ID: 19830741)
21. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
[TBL] [Abstract][Full Text] [Related]
22. Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination.
Reuter A; Panozza SE; Macri C; Dumont C; Li J; Liu H; Segura E; Vega-Ramos J; Gupta N; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
J Immunol; 2015 Mar; 194(6):2696-705. PubMed ID: 25653426
[TBL] [Abstract][Full Text] [Related]
23. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals.
Njongmeta LM; Bray J; Davies CJ; Davis WC; Howard CJ; Hope JC; Palmer GH; Brown WC; Mwangi W
Vaccine; 2012 Feb; 30(9):1624-35. PubMed ID: 22240344
[TBL] [Abstract][Full Text] [Related]
24. Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.
Bozzacco L; Yu H; Dengjel J; Trumpfheller C; Zebroski HA; Zhang N; Küttner V; Ueberheide BM; Deng H; Chait BT; Steinman RM; Mojsov S; Fenyö D
PLoS One; 2012; 7(7):e41897. PubMed ID: 22860026
[TBL] [Abstract][Full Text] [Related]
25. Flt3L-mobilized dendritic cells bearing H2-Kbm1 apoptotic cells do not induce cross-tolerance to CD8+ T cells across a class I MHC mismatched barrier.
del Rio ML; Cote-Sierra J; Rodriguez-Barbosa JI
Transpl Int; 2011 May; 24(5):501-13. PubMed ID: 21276089
[TBL] [Abstract][Full Text] [Related]
26. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
[TBL] [Abstract][Full Text] [Related]
27. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.
Leung CS; Maurer MA; Meixlsperger S; Lippmann A; Cheong C; Zuo J; Haigh TA; Taylor GS; Münz C
Blood; 2013 Feb; 121(9):1584-94. PubMed ID: 23297134
[TBL] [Abstract][Full Text] [Related]
28. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.
Maraskovsky E; Brasel K; Teepe M; Roux ER; Lyman SD; Shortman K; McKenna HJ
J Exp Med; 1996 Nov; 184(5):1953-62. PubMed ID: 8920882
[TBL] [Abstract][Full Text] [Related]
29. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
[TBL] [Abstract][Full Text] [Related]
30. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.
Bandyopadhyay A; Fine RL; Demento S; Bockenstedt LK; Fahmy TM
Biomaterials; 2011 Apr; 32(11):3094-105. PubMed ID: 21262534
[TBL] [Abstract][Full Text] [Related]
31. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.
Tacken PJ; Ginter W; Berod L; Cruz LJ; Joosten B; Sparwasser T; Figdor CG; Cambi A
Blood; 2011 Oct; 118(15):4111-9. PubMed ID: 21860028
[TBL] [Abstract][Full Text] [Related]
32. Targeting DEC-205
Tabansky I; Keskin DB; Watts D; Petzold C; Funaro M; Sands W; Wright P; Yunis EJ; Najjar S; Diamond B; Cao Y; Mooney D; Kretschmer K; Stern JNH
Mol Med; 2018 May; 24(1):17. PubMed ID: 30134798
[TBL] [Abstract][Full Text] [Related]
33. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
34. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice.
Stylianou E; Pepponi I; van Dolleweerd CJ; Paul MJ; Ma JK; Reljic R
Vaccine; 2011 Mar; 29(12):2279-86. PubMed ID: 21272603
[TBL] [Abstract][Full Text] [Related]
35. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
Gurer C; Strowig T; Brilot F; Pack M; Trumpfheller C; Arrey F; Park CG; Steinman RM; Münz C
Blood; 2008 Aug; 112(4):1231-9. PubMed ID: 18519810
[TBL] [Abstract][Full Text] [Related]
36. Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune Response.
Fossum E; Tesfaye DY; Bobic S; Gudjonsson A; Braathen R; Lahoud MH; Caminschi I; Bogen B
J Immunol; 2020 Aug; 205(3):661-673. PubMed ID: 32591401
[TBL] [Abstract][Full Text] [Related]
37. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice.
Mukhopadhaya A; Hanafusa T; Jarchum I; Chen YG; Iwai Y; Serreze DV; Steinman RM; Tarbell KV; DiLorenzo TP
Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6374-9. PubMed ID: 18430797
[TBL] [Abstract][Full Text] [Related]
38. In vivo administration of Fms-like tyrosine kinase-3 ligand effectively stimulates lung dendritic cell expansion in mice.
Wang HW; Lu JY; Wang L; Tian G
Chin Med J (Engl); 2012 Jul; 125(14):2562-7. PubMed ID: 22882940
[TBL] [Abstract][Full Text] [Related]
39. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
40. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.
Tenbusch M; Nchinda G; Storcksdieck genannt Bonsmann M; Temchura V; Überla K
Int Immunol; 2013 Apr; 25(4):247-58. PubMed ID: 23184617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
